Abstract：
To characterize HPV genotype distribution in HSIL and ICC- biopsies, of WLWH, in Europe, as compared to HIV-negative women.
Cohort- and nested -case control study.
We characterized HPV genotype distribution by performing PCR on HSIL and ICC biopsies from WLWH (n = 170); 85 cases were compared to 85 HIV-negative matched controls. The proportion of patients that might be protected by HPV vaccines was estimated.
Among WLWH (median age 36 years-old, median duration of HIV infection 70,5 months, 79% under cART): the most frequently detected HPV were HPV16 (30%), HPV35 (16%), HPV58 (14,7%), HPV31 (13,5%), and HPV52 (11,7%). HPV16 was less frequently found in WLWH, originating from Central Africa (20,5%) compared to other African regions (35,5%) (p = 0,05) or world regions (38,8%) (p = 0,007). Multiple versus single high-risk HPV infections were associated with younger age (≤35 years)(odds ratio (OR) 2,65 (95%IC: 1,3-5,2,p = 0,002), lymphocyte CD4 count < 350 cells / µL (OR 2,7 (95%IC: 2-8,5; p = 0,005), use of cART for < 18 month OR 2,2 (95%IC: 1,1-4,5),p = 0,04) or a cumulative time with undetectable HIV viral load of less than 12 months (OR 4,2 (95%IC: 2-8.5,p = 0,001). HPV 31, 33 and 35 were more frequently detected in samples from WLWH than in HIV-negative controls (p < 0,05). The 9-valent vaccine would increase HPV protection, in HIV-positive and negative women (p < 0,001).
WLWH are more frequently infected with high-risk HPV other than 16 and 18 than HIV-negative ones. The use of 9-valent vaccine may prevent HSIL or ICC in up to 85% of the women. Adding HPV 35 to the HPV vaccine panel, might improve vaccine effectiveness in WLWH.
Cohort- and nested -case control study.
We characterized HPV genotype distribution by performing PCR on HSIL and ICC biopsies from WLWH (n = 170); 85 cases were compared to 85 HIV-negative matched controls. The proportion of patients that might be protected by HPV vaccines was estimated.
Among WLWH (median age 36 years-old, median duration of HIV infection 70,5 months, 79% under cART): the most frequently detected HPV were HPV16 (30%), HPV35 (16%), HPV58 (14,7%), HPV31 (13,5%), and HPV52 (11,7%). HPV16 was less frequently found in WLWH, originating from Central Africa (20,5%) compared to other African regions (35,5%) (p = 0,05) or world regions (38,8%) (p = 0,007). Multiple versus single high-risk HPV infections were associated with younger age (≤35 years)(odds ratio (OR) 2,65 (95%IC: 1,3-5,2,p = 0,002), lymphocyte CD4 count < 350 cells / µL (OR 2,7 (95%IC: 2-8,5; p = 0,005), use of cART for < 18 month OR 2,2 (95%IC: 1,1-4,5),p = 0,04) or a cumulative time with undetectable HIV viral load of less than 12 months (OR 4,2 (95%IC: 2-8.5,p = 0,001). HPV 31, 33 and 35 were more frequently detected in samples from WLWH than in HIV-negative controls (p < 0,05). The 9-valent vaccine would increase HPV protection, in HIV-positive and negative women (p < 0,001).
WLWH are more frequently infected with high-risk HPV other than 16 and 18 than HIV-negative ones. The use of 9-valent vaccine may prevent HSIL or ICC in up to 85% of the women. Adding HPV 35 to the HPV vaccine panel, might improve vaccine effectiveness in WLWH.
摘要：
为了表征HSIL和ICC活检中的HPV基因型分布，WLWH,在欧洲,与艾滋病毒阴性的女性相比。
队列和嵌套病例对照研究。
我们通过对来自WLWH（n=170）的HSIL和ICC活检进行PCR来表征HPV基因型分布；将85例病例与85例HIV阴性匹配对照进行比较。估计了可能受到HPV疫苗保护的患者比例。
在WLWH（中位年龄36岁，HIV感染的中位持续时间为70,5个月，在cART下79%)：最常检出的HPV是HPV16(30%)，HPV35（16%），HPV58（14,7%），HPV31（13,5%），和HPV52（11,7%）。在WLWH中发现HPV16的频率较低，源自中部非洲（20,5％），而其他非洲区域（35,5％）（p=0.05）或世界区域（38,8％）（p=0.007）。多重与单一高危HPV感染与年龄较小（≤35岁）相关（比值比（OR）2,65（95％IC：1,3-5,2，p=0,002），淋巴细胞CD4计数<350个细胞/μL（OR2,7（95％IC：2-8,5；p=0,005），使用cART<18个月OR2,2(95%IC：1,1-4,5)，p=0.04）或无法检测到的HIV病毒载量少于12个月的累积时间（OR4,2（95％IC：2-8.5，p=0,001）。在来自WLWH的样品中比在HIV阴性对照中更频繁地检测到HPV31、33和35(p<0.05)。9价疫苗将增加HPV保护，艾滋病毒阳性和阴性妇女(p<0.001)。
与HIV阴性相比，WLWH感染除16和18以外的高危HPV的频率更高。9价疫苗的使用可以预防多达85％的妇女的HSIL或ICC。将HPV35添加到HPV疫苗组中，可能会提高WLWH疫苗的有效性。
队列和嵌套病例对照研究。
我们通过对来自WLWH（n=170）的HSIL和ICC活检进行PCR来表征HPV基因型分布；将85例病例与85例HIV阴性匹配对照进行比较。估计了可能受到HPV疫苗保护的患者比例。
在WLWH（中位年龄36岁，HIV感染的中位持续时间为70,5个月，在cART下79%)：最常检出的HPV是HPV16(30%)，HPV35（16%），HPV58（14,7%），HPV31（13,5%），和HPV52（11,7%）。在WLWH中发现HPV16的频率较低，源自中部非洲（20,5％），而其他非洲区域（35,5％）（p=0.05）或世界区域（38,8％）（p=0.007）。多重与单一高危HPV感染与年龄较小（≤35岁）相关（比值比（OR）2,65（95％IC：1,3-5,2，p=0,002），淋巴细胞CD4计数<350个细胞/μL（OR2,7（95％IC：2-8,5；p=0,005），使用cART<18个月OR2,2(95%IC：1,1-4,5)，p=0.04）或无法检测到的HIV病毒载量少于12个月的累积时间（OR4,2（95％IC：2-8.5，p=0,001）。在来自WLWH的样品中比在HIV阴性对照中更频繁地检测到HPV31、33和35(p<0.05)。9价疫苗将增加HPV保护，艾滋病毒阳性和阴性妇女(p<0.001)。
与HIV阴性相比，WLWH感染除16和18以外的高危HPV的频率更高。9价疫苗的使用可以预防多达85％的妇女的HSIL或ICC。将HPV35添加到HPV疫苗组中，可能会提高WLWH疫苗的有效性。
